Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Position-effect Variegation02:32

Position-effect Variegation

In 1928, a German botanist Emil Heitz observed the moss nuclei with a DNA binding dye. He observed that while some chromatin regions decondense and spread out in the interphase nucleus, others do not. He termed them euchromatin and heterochromatin, respectively. He proposed that the heterochromatin regions reflect a functionally inactive state of the genome. It was later confirmed that heterochromatin is transcriptionally repressed, and euchromatin is transcriptionally active chromatin.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gene fusions in non-small cell lung carcinoma (NSCLC): Expert perspectives and practical considerations for routine testing.

Critical reviews in oncology/hematology·2026
Same author

Standardized Analytical Verification of ctDNA ESR1 Mutation Testing in Metastatic HR+/HER2- Breast Cancer: A European Multicentre Study Using dPCR and NGS-Based Liquid Biopsy.

Molecular diagnosis & therapy·2026
Same author

Centralized Homologous Recombination Repair Testing in Metastatic Castration-Resistant Prostate Cancer: Real-World Data from a Multicenter Spanish Precision Oncology Program.

Cancers·2026
Same author

Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer.

Neoplasia (New York, N.Y.)·2026

Related Experiment Video

Updated: May 22, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Are ER+PR+ and ER+PR- breast tumors genetically different? A CGH array study.

Alma Carracedo1, Marta Salido, Josep M Corominas

  • 1Pathology Service, Molecular Cytogenetics Laboratory, Hospital del Mar, IMIM, Barcelona, Spain.

Cancer Genetics
|May 8, 2012
PubMed
Summary

Estrogen receptor-positive, progesterone receptor-negative (ER+PR-) breast tumors exhibit distinct genomic alterations compared to ER+PR+ tumors. These genomic differences may explain their aggressive nature and poorer response to endocrine therapy.

More Related Videos

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

Related Experiment Videos

Last Updated: May 22, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Estrogen receptor (ER) status predicts breast cancer response to endocrine therapy.
  • ER-positive, progesterone receptor-negative (ER+PR-) tumors show poorer treatment response and more aggressive phenotypes than ER+PR+ tumors.

Purpose of the Study:

  • To compare the genomic profiles of ER+PR- and ER+PR+ breast tumors.
  • To identify specific genomic alterations associated with the ER+PR- phenotype.

Main Methods:

  • Comparative genomic hybridization (CGH) array analysis of 23 ER+PR- and 25 ER+PR+ tumors.
  • Validation using tissue microarrays (50 ER+PR- and 50 ER+PR+) and fluorescence in situ hybridization (FISH).

Main Results:

  • ER+PR- tumors displayed a distinct genomic profile compared to ER+PR+ tumors.
  • Significant differences in copy number alterations were observed on chromosomes 3, 8, 9, 14, 17, 20, 21, and 22.
  • Specific gained regions (e.g., 17q23.2-q23.3, 20q13.12) and lost regions (e.g., 3p21.32-p12.3, 9pter-p13.2) were statistically significant in ER+PR- tumors.
  • Lost regions contained tumor suppressor genes and genes involved in apoptosis, mitosis, angiogenesis, and cell spreading.
  • Gained regions included genes like MAP3K3, RPS6KB1, and ZNF217, potentially linked to apoptosis resistance and PI3K/Akt/mTOR pathway activation.

Conclusions:

  • ER+PR- breast tumors possess a unique genomic signature differentiating them from ER+PR+ tumors.
  • Genomic alterations in ER+PR- tumors may contribute to their aggressive behavior, resistance to apoptosis, and loss of PR expression.